Journal of Medicinal Chemistry

© Copyright 1968 by the American Chemical Society

VOLUME 11, NUMBER 2

FEBRUARY 26, 1968

Application of Regression Analyses to Antitumor Activities of Various Acetylenic Carbamates¹

WILLIAM P. PURCELL AND JOHN M. CLAYTON

Department of Medicinal Chemistry, University of Tennessee College of Pharmacy, Memphis, Tennessee 38103

Received October 25, 1967

Regression analyses by the Free and Wilson method² were applied to the tumor inhibition (per cent inhibition/mg of drug per kg of test animal) and cure potency (per cent prolongation of life/mg of drug per kg of test animal) of 69 substituted acetylenic carbamate analogs.⁸ The original biological response parameters yielded more meaningful results than logarithms of these data. For regressions considered of predictive value, correlations were significant at greater than the 90% level. It was found that statistical tests alone are not always reliable means of judging the predictive utility of regressions of this type. Compounds predicted to be most active against these tumors were among those not tested; some of the more promising compounds would contain 2-naphthyl, 4-fluorophenyl, or phenyl groups or combinations of them at the nitrogen with cyclohexyl, cycloheptyl, or cyclopentyl groups or combinations at the 1,1-(2-propynyl) positions. In compounds with the highest calculated activities, substituents on the nitrogen appear to contribute more to the total activity than do substituents at the 1,1-(2-propynyl) positions.

In the search for a method of accurate prediction of therapeutically active molecules for specific pharmacological actions, the application of regression analyses, of both the mathematical^{2,3} and linear free-energy^{4,5} models, continues to hold much promise and interest. In consideration of the labor of synthesis and testing associated with drug development, any mechanism suggesting molecules having a high probability of success would be invaluable. An apparently good correlation was found, for example, in the application of Free and Wilson's method² to an analogous series of cholinesterase inhibitors.⁶ More recently, application of this technique to hypoglycemic activities of several piperidinesulfamyl semicarbazides has also given interesting results.⁷

For meaningful application of the Free and Wilson model,² the biological data should meet three basic prerequisites: (1) molecules in the series should be closely similar (to increase the probability of a constant mechanism of action), (2) biological activity selected should be accurate, quantitative, and measured under uniform conditions for the series, and (3) the group contributions (to the chosen activity parameters) must be intrinsically additive. Also, it is desirable for the data to have a high number of degrees of freedom since the greater the ratio of number of ob-

(6) W. P. Purcell, Biochim. Biophys. Acta. 105, 201 (1965).

servations to number of unknowns, the more significant are the results.

Dillard, et al.,⁸ have recently reported experimental results⁹ of the antitumor activities of 85 acetylenic carbamates, most of which are well suited for application of the regression analysis. Following the procedures of Johnson, et al.,¹⁰ the antitumor activities of various analogs of the substituted acetylenic carbamates (I) were tested against subcutaneously im-

$$R$$
 $CC = CH$ I

planted tumors in mice.⁸ The tumors used were X5563, a plasma-cell tumor, and C1498, an atypical myelogenous leukemia.⁸ Dillard, *et al.*,⁸ reported the per cent inhibition of the tumor X5563 and the per cent prolongation of life for those animals with tumor C1498. We analyzed these data (1) to rank the anti-tumor activities of the substituent groups and note possible structure-activity relationships, and (2) to predict the compounds of the series not tested, and possibly not synthesized, which would have the greatest potential as tumor inhibitors.

Calculations.—By assuming the activity contributions of the substituent groups on the parent structure to be constant and additive to the total activity of the

⁽¹⁾ This research is being supported by the U. S. Army Medical Research and Development Command (DA-49-193-MD-2779) and the National Science Foundation (GB-4453). This paper is Contribution No. 283 from the Army Research Program on Malaria. Computer facilities were provided through Grant HE-09495 from the National Institutes of Health.

⁽²⁾ S. M. Free, Jr., and J. W. Wilson, J. Med. Chem., 7, 395 (1964).

⁽³⁾ J. Kopecky, K. Boček, and D. Vlachová, Nature, 207, 981 (1965).

⁽⁴⁾ C. Hansch and T. Fujita, J. Am. Chem. Soc., 86, 1616 (1964).

⁽⁵⁾ C. Hansch, E. W. Deutsch, and R. N. Smith, ibid., 87, 2738 (1965).

⁽⁷⁾ W. R. Smithfield and W. P. Purcell, J. Pharm. Sci., 56, 577 (1967).

⁽⁸⁾ R. D. Dillard, G. Poore, D. R. Cassady, and N. R. Easton, J. Med. Chem., 10, 40 (1967).

⁽⁹⁾ It should be recognized that the authors⁸ noted that the activities reported "are the results of a specific dose-response test for each compound and should be considered in a qualitative manner in comparing relative potencies." This limitation should not be overlooked when analyzing the results of the regression.

⁽¹⁰⁾ I. S. Johnson, H. F. Wright, G. H. Svoboda, and J. Vlantis, *Cancer Res.*, **20**, 1016 (1960).

molecule, the data of Dillard, *et al.*,⁸ were analyzed according to the method of Free and Wilson,² For this model, one generates a linear equation for each observation (*e.g.*, eq. 1) where a. b. c. and d represent

$$[C_6H_5]_n + [C_6H_5]_b + [H]_e + [CH_3]_d + \mu = 7.533$$
(1)

positions R, R₁, R₂, and R₃, respectively, on the parent structure while the brackets indicate the activity contribution of the substituent group at that position to the total activity; μ represents the activity contribution of the parent structure. Thus, $[C_6H_5]_a$ is the activity contribution of a phenyl group at position R; $[C_6H_5]_b$ represents the activity contribution of a phenyl group at position R₁; $[H]_c$ is the activity contribution of a hydrogen at position R₂; and $[CH_3]_d$ is the activity contribution of a methyl group at position R₃. The sum of these individual group contributions plus μ in each equation is equal to the biological response parameter (eq 2). In searching for

Biological Response =
$$\mu + \Sigma$$
 group contributions (2)

a biological response parameter which could be used comparatively, the antitumor activity percentages reported by Dillard, *et al.*,⁸ divided by the dosages (mg/kg) administered to the test animals were selected. Thus, the activity contributions in these regressions were set equal to the per cent inhibition of the tumor/mg of drug per kg of the test animal in system X5563 and the per cent prolongation of life/ mg of drug per kg of the animals tested with tumor C1498 (e.g., biological response in eq 1 is 7.533%prolongation of life/mg per kg).

From the assumption that position R is equivalent to position R_1 , and R_2 is equivalent to R_3 , the linear equations can be simplified by reducing the number of unknowns. For example, eq. 1 reduces to eq.3. One

$$2[C_6H_5]_a + [H]_e + [CH_3]_e + \mu = 7.533$$
 (3)

can then generate 65 simultaneous equations with 36 unknowns for system X5563 and 69 equations with 37 unknowns for tumor C1498. In addition, following the method of Free and Wilson,² two restrictions (symmetry equations) were applied, namely, summations to zero of the group contributions at positions R_1R_1 and R_2R_3 . The 67 simultaneous equations for system X5563 and the 71 simultaneous equations for tumor C1498 were then solved independently by the method of least squares using the IBM 1620 computer.

Results and Discussion

Least-squares solution of the linear equations yielded the calculated activity contribution of each substitnent group as well as that of the parent structure. The calculated total activity of each molecule was found by summation of these group contributions and μ (eq. 2). These calculated activities were then plotted against the observed biological activities; most of the points were very near the 45° line of the graph, indicating a relatively good correlation between the two sets of values. It was observed, however, that certain groups (cyclohexyl, propynyl, and tetramethylene) substituted at positions R₂,R₃ probably possessed nonadditive properties because there were large deviations between their corresponding points (plot of tumor X5563) and the ideal 45° line. Of these, only the cyclohexyl group, which had the highest calculated activity, exhibited an activity contribution (5.040 $^{c_{c}}$ inhibition/mg per kg) sufficient to be considered as active. Similarly, the regression analysis of system C1498 indicated that three substituent groups (cyclohexyl, tetramethylene, and ethyl) exhibited nonadditive activity contribution properties. Here, too, the magnitude of the activity contribution of only the cyclohexyl group (6.679% prolongation of life/mg per kg) warrants its consideration in potential antitumor agents of this type.

These observations prompted the deletion of data obtained from the "nonadditive" groups, and the simultaneous equations were once again solved.

From the results of these second analyses, the ranks of antitumor activity contributions by the substituted groups in each tumor system were found to be quite similar (Table I). It was observed that 5 of the 18 groups substituted at positions R_2R_3 contributed 14 groups substituted at positions R_2R_3 contributed constructively (positive sign, Table I) to the antitumor activity of the compounds tested against tumor X5563. On the other hand, only 3 out of the

TAULE I
SUBSTITUENT GROUP CONTRIBUTION TO
ANTITUMOR ACTIVITY

Tamor 1	X5563	Rauk		1498~
Group	$\Delta e(\mathbf{i} \mathbf{v}^{n} \mathbf{v}^{n})$		Group	Activity ⁶
	Substituents	at Po	sition R_1R_1	
2-C ₁₀ H ₇	2.604	1	2-C ₁₀ H	2.047
4-FC ₆ H ₄	1.162	2	4-FC ₆ H ₄	1.499
1-C ₁₀ H ₇	0.675	3	$C_6\Pi_5$	1.240
$ClCH_2$	0.570	4	$4-\mathrm{ClC_{5}H_{1}}$	10.381
C_6H_5	(1, 570)	5	$1 - C_{10} H_{1}$	-1.297
$4\text{-}\mathrm{ClC_6H_4}$	-0.025	6	$4 \text{-IC}_{6}\text{H}_{4}$	-1.341
$4-1C_{6}H_{4}$	()435i	7	4-C ₆ H ₅ C ₆ H ₄	-1.845
4-BrC ₆ II.	-1.012	8	4-BrC ₆ II ₄	-2.176
$2-C_5H_4N$	-2.4151	9	$3, 4$ - $Cl_2C_6U_5$	-3.416
$2-C1C_6H_4$	-2.246	10	$2,4-Cl_2C_6H_3$	3.416
3-ClC ₆ H ₄	-2.322	11	3-CIC ₆ H ₄	
2,4-Cl ₂ C ₆ H ₃	-2.360	12	$3-{ m BrC_6H_1}$	3.665
3,4-CI ₂ C ₆ H ₄	-2.382	13	$C\Pi_3$	-3.697
CH_3	-2.657	l 4	II	-3.697
H	-2.657	15	$4 - CF_3C_6H_4$	3.697
$4-O_2NC_6H_1$	-2.657	16	$4 - CH_3C_6H_4$	-3.697
$4-CH_{3}C_{6}H_{3}$	-2.657	17	$2\text{-}C_4H_3S$	-3.697
2-CH_3S	~2.457	18	2-ClC ₆ H,	-3.970
		19	$2 \cdot C_{b}H_{4}N$	-4.087
	Substituents	at Po	sition R_{\sharp}, R_{\sharp}	
Cycloheptyl	3,407	ł	Cyclopentyl	5.555
CH2CH==CH2	1.265	2	Cycloheptyl	4.285
Cyclopentyl	1.207	3	$CH_2CH=CH_2$	1.141
$(CH_2)_3N(CH_2)$	$_{2} = -0.873$	4	CH₂C≡CH	0.589
CH_3	0.372	5	CH ₃	0.412
Cyclooetyl	0.073	6	11	0.021
C_2H_5	-0.027	5	$(CH_2)_3N(CH_3)_2$	-1.915
Н	-0.033	8	Cyclopropyl	-2.315
$\mathrm{CH}_{2}\mathrm{CH}_{2}\mathrm{C}_{6}\mathrm{H}_{5}$	-2.477	9	Cyclooctył	-2.348
$4-\mathrm{ClC}_6\mathrm{H}_4$	-3,060	10	$\rm NH_2$	-4.248
Cyclopropyl	-3.260	11	$\mathrm{CH}_2\mathrm{CH}_2\mathrm{C}_6\mathrm{H}_5$	-4.582
$\mathrm{CH_{2}CH_{2}OH}$	3 . 260	12	$4-\mathrm{ClC_6H_5}$	-4.675
$\mathrm{CH}_2\mathrm{C}_6\mathrm{H}_5$	-3.260	13	CH ₂ CH ₂ OH	-4.915
NH_2	-3.260	14	$\rm CH_2C_6H_5$	-4.915

^a Activity is given as per cent inhibition of the tumor/mg of drug per kg of the test animal. ^b Activity is given as per cent prolongation of life/mg of drug per kg of the test animal.

TABLE II

Observed and Calculated Antitumor Activity of Various Substituted Acetylenic Carbamates against Tumor X5563

OCONR₂R₃

					— s	ubst	itue	nts a	it po	sitic	on R	Rı-									-Sul	ostit	uen	ts at	pos	itio	n R2	.R₃-	_				
CICIE	- CII3	$C_{6}\Pi_{5}$	II	4-CIC6114	3-0106114	2-CICeIL	3,4-Cl ₂ C ₆ H ₃	2,4-Cl ₂ C ₄ H ₃	4-BrC ₆ II ₄	4~FC%H4	4-1C5H4	4-02NC6H4	4-CH3CelL	$2-C_{10}H_7$	$1-C_{10}H_7$	2-CsH4N	2-C4H3S	Нo	CH3	C ₂ H ₅	$CH_2CH_{\Xi} = CH_2$	Cyclopropyl	CII2CH2OH	CH2C5H5	CH2CH2C6H5	Cyclopentyl	Cycloheptyl	Cyclooetyl	(CH2)3N (CH3)2	4-ClC6114	$N H_2$	Ant: act Obsd 0,000	itu ivi
		$1 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ 2 \\ $	1	$ \begin{array}{c} 1 \\ 1 \\ 1 \end{array} $ 2 2	1 1 1 1	1 1	11	1	1 1 1 1	1 1	1	1	1	11	1	1111	1	2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1	1	1	1	1	1	1	1	1	1	1	1	0.000 0.000 2.213 4.267 3.233 5.555 0.000 0.000 0.000 0.783 4.467 6.667 3.333 4.133 0.200 0.000 4.333 0.200 0.000 4.333 0.200 0.000 4.333 0.000 2.500 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.200 2.900 3.333 0.000 1.111 1.111 0.722 0.160 0.493 0.000 1.583 1.667 2.222 0.000 6.667 2.222 0.000 8.000 3.333 3.333 0.667 1.533 0.833 0.000 1.550 4.167	

^a Activity is given as per cent inhibition of tumor/mg of drug per kg of test animal. ^b Calculated using eq[2 where $\mu = 2.153\%$ inhibition of tumor/mg of drug per kg of test animal.

TABLE III

Observed and Calculated Antitumor Activity of Various Substituted Acetylenic Carbamates against Tumor C1498

$\begin{array}{c} 0 CONR_{\sharp}R_{\sharp}\\ R_{\star} & = \\ CC \Longrightarrow CH\\ R_{\star} \end{array}$

~						Subs	titu	enis	at	posi	tion	R, F	≀		1	Ω′ 	·	·				Sal	batil	uen	ls a	Сря	ositio	on I	₹ : , R			·····		
Nu. C	CH	п	4-CIC ₆ II ₄	3-CICeII ₄	2-CIC ₆ II ₄	3,4-Cl2C411,	2,4-Cl2C6113	4-BrCall4	3-BrC6114	4-FC6H	1-J C6HJ	4-CF2C6H4	4-CHaCalla	4-C ₆ H ₆ C ₆ H,	2-C ₁₀ H7	1-C ₁₀ 11 ₇	2-0311/N	$2 - C_4 \prod_{3} N$	=	- CIIa	$CH_2CH \rightarrow CH_2$	CHPCE CH	Сусюнгонуі	HOfHOfHO	C'11 ₂ C'611.	CH4CH4CaH5	Cyclopentyl	Cycholendyl	Cyclotyl	$(\mathrm{CH}_2)_3\mathrm{N}(\mathrm{CH}_3)_2$	4-CIC ₆ IL	N 112	Aut ari Obsd 7 533	(lamor iví(y ⁰ Ca)el ⁶ 5-397
$\begin{array}{c} 112 \\ 22 \\ 22 \\ 22 \\ 22 \\ 22 \\ 22 \\ 22$		-	1 I I I I I I I I I I I I I I I I I I I	3-CIC6H	2-CIC6H	1 - 1 - 1	1 1	1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-	a	1-1-CeH1	-10%IL	1-CH ₂ C ₆	1)°(1)°(1)	1-1.	2.C(:@ll7	1-Ciolb	2-45/H/N	2-0,411/8	= 1 + 1 + 1 + 1 + 1 + 1 + 1 + 1 + 2 + 2 +	*III) 1 2 1 2 2	- Clif(3)	्र)गित) 1	- (yelone	۴(۱۲)	- (11 ² C ₃ 11	۶۱۱, yéll,)	(), cloter	- Cyclule	- Cycloris	- (CIII ₃) _x N		- III	$\begin{array}{c} \lambda m\\ a^{ee}\\ 0bsd\\ \hline\\ 7,533\\ 6,056\\ 5,600\\ 2,600\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 2,567\\ 3,000\\ 0,240\\ 0,667\\ 4,533\\ 0,000\\ 0,240\\ 0,2525\\ 2,300\\ 2,067\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 1,089\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 0,000\\ 1,367\\ 2,367\\ 0,473\\ 2,140\\ 5,667\\ 13,800\\ 0,000\\ 3,1350\\ 0,000\\ 3,1350\\ 0,800\\ 0,00$	$\begin{array}{llllllllllllllllllllllllllllllllllll$
$\begin{array}{cccccccccccccccccccccccccccccccccccc$			22211			1	1			2 2					1	ł	1	1	- 224 - 224 - 222	$\frac{2}{1}$ $\frac{1}{2}$ $\frac{1}{2}$													$\begin{array}{c} 5.840\\ 5.467\\ 2.400\\ 0.000\\ 0.000\\ 0.000\\ 1.000\\ 4.625\\ 1.400\\ 0.000\\ 0.000\\ 2.686\\ 6.667\end{array}$	$\begin{array}{c} 3, (43)\\ 6, 524\\ 2, 100\\ -0, 390\\ 0, 390\\ 0, 000\\ 1, 694\\ 2, 084\\ 2, 084\\ -1, 341\\ -1, 341\\ 5, 454\\ 6, 235\end{array}$

^a Activity is given in per cent prolongation of life/nig of drug per kg of test animal. ^b Calculated using eq 2 where $\mu = 2.414C_{c}$ prolongation of life/mg of drug per kg of test animal.

19 groups substituted at positions R,R_1 and 6 groups of 14 substituted at R_2,R_3 were not deleterious to the activity of those compounds inhibiting tumor C1498. Also, these rankings were noticeably similar to those of the original regressions in that the number of active groups was the same in each and many of them were in the same relative order. Too, the significance of the correlation increased markedly in the second regressions indicating that statistically they are considerably better: the correlation coefficient, level of significance of F ratio,¹¹ and Ψ^{12} for system X5563 changed from 0.816, 0.940, and 0.578 to 0.915, 0.995, and 0.403, respectively, while the corresponding values for system C1498 went from 0.800, 0.900–0.950, and 0.600 to 0.882, 0.975–0.995, and 0.471, respectively

for system C1498 went from 0.800, 0.900–0.950, and 0.600 to 0.882, 0.975–0.995, and 0.471, respectively. Tables II and III give the calculated and observed activities for the second regression analyses. Included in the total calculated activities is the calculated value of μ for each system; $\mu = 2.153\%$ inhibition of tumor/mg of drug per kg of test animal for tumor X5563 and $\mu = 2.414\%$ prolongation of life/mg of drug per kg of test animal in system C1498. Deviations between the calculated and observed activities for most observations are quite small; of course, there is necessarily no activity deviation for those compounds with substituent groups observed only once.

In other attempts to find a more significant regression, the linear equations were solved using the logarithms of the biological responses as the activity parameters since logarithms of biological activity data are often considered free-energy related, and therefore may be additive. These calculations were based on all substituent groups analyzed in the first calculations (i.e., no groups of the original data were deleted in these regressions). From calculation of the Fratios,¹¹ Ψ ,¹² and correlation coefficients, it was found that these regressions of logarithms were statistically better than the original calculations. In order to make a valid comparison of the degree of fit between the linear data and logarithmic data, calculated total activity was plotted against the observed total activity for each observation using the antilogarithms of the results of the logarithmic regression. Table IV summarizes the statistical results and makes it clear that the preferred choice of biological response parameter for tumor C1498 is the original linear data and not their logarithms.

It is important to emphasize that one could be misled from the statistics of the regression analysis using the logarithms of the original linear data (correlation coefficient = 0.927, level of F ratio¹¹ = 0.995, $\Psi^{12} = 0.373$) which are better than those for the original linear data (Table IV). Statistical calculations (correlation coefficient, F ratio,¹¹ and Ψ^{12}) alone are not suitable as a means of judging the predictive utility of regression analyses of this type.

Perhaps the most interesting point in this study is the fact that several molecules which were not tested *in vivo* have calculated antitumor activities greater

TABLE IV Statistical Results of Regression Analyses of Linear and Logarithmic Data (System C1498)

Results of regression analysis of	Cor coef	Signif of F ratio ^a	Ψ^b	Σ (obsd caled) ² c
Original linear data	0.800	0.90-0.95	0.600	527.6
Logarithms of original				
linear data (results				
converted to anti-				
logarithms)	0.636	<0.75	0.793	920.8
^a Reference 11. ^b Reference the observed and c	.ce 12. – alculated	Sum of squa d activities.	res of de	eviations

than those tested. It would appear that the best compounds would contain 2-naphthyl, 4-fluorophenyl, or phenyl groups or combinations of them substituted at positions R and R_1 with cyclohexyl, cycloheptyl, or cyclopentyl groups or combinations at R_2 and R_3 . For example, the calculated activity of the molecule, 1,1-(2,2'-dinaphthyl)-2-propynyl N,N-dicycloheptylcarbamate, with 2-naphthyl groups substituted at positions R and R₁ and cycloheptyl groups substituted at R_2 and R_3 is 14.175% inhibition/mg per kg against tumor X5563 while the most potent molecule tested, 1-(2-naphthyl)-1-phenyl-2-propynyl carbamate, had an observed activity of only 8.000% inhibition/mg per kg. On the other hand, when 2-naphthyl groups are substituted at positions R and R_1 along with cyclopentyl groups at R2 and R3, the molecule, 1,1-(2,2'-dinaphthyl)-2-propynyl N,N-dicyclopentylcarbamate, exhibits a calculated activity of 17.618% prolongation of life/ mg per kg against tumor C1498 compared with the 13.800% prolongation of life/mg per kg of 1-(4-fluorophenyl)-1-phenyl-2-propynyl N,N-dimethylcarbamate which is the highest observed activity. One would conclude that these and similar promising compounds are worthy of synthesis and testing.

In the more active molecules of this series, substituents at positions R₂ and R₃ contribute more to the calculated total activity of the molecule than do substituents at R and R₁. An example of this is 1,1-diphenyl-2-propynyl N-cyclopentylcarbamate (8, Table III), the compound tested with the highest calculated total activity. Of the total calculated activity of 10.467% prolongation of life/mg per kg, an activity of only 2.480% prolongation of life/mg per kg was contributed by positions R and R_1 compared with 5.576% prolongation of life/mg per kg contributed by positions R_2 and R_3 . This observation holds true uniquely well for those molecules predicted as potent antitumor agents and is also illustrated in Table I; the calculated activities of the more potent substituent groups at R and R_1 (2.047 and 1.499% prolongation of life/mg per kg) are only half these of the more active substituent groups at R_2 and R_3 (5.555 and 4.285% prolongation of life/mg per kg).

Acknowledgment.—The authors wish to thank Mr. M. M. Marsh, Dr. N. R. Easton, and Mr. R. D. Dillard of the Lilly Research Laboratories for their helpful comments on the manuscript. They also wish to thank Mr. K. Sundaram and Miss J. A. Singer for reading and commenting on the manuscript.

⁽¹¹⁾ G. W. Snedecor, "Statistical Methods," 5th ed. The Iowa State College Press, Ames, Iowa, 1956, pp 417-420, 276-279.

⁽¹²⁾ O. Exner, Collection Czech. Chem. Commun., 31, 3222 (1966).